FDA Brief

Warning letters Drugs

FDA warning letter to

citypharma.us

High riskIssued May 22, 2023Posted May 30, 2023Center for Drug Evaluation and Research | CDER

FDA warned citypharma.us for selling unapproved, misbranded opioid, benzodiazepine, and stimulant drugs to U.S. consumers online.

What happened

FDA reviewed the website www.citypharma.us and found it offered unapproved and misbranded drugs for sale to U.S. consumers, including tramadol as “Citra 100 mg,” clonazepam as “Rivotril 2mg,” and amphetamine as “Adderall 10mg.” FDA said the site offered prescription drugs without a prescription and that labels lacked adequate directions for use. There was no inspection; FDA’s finding came from a website review.

What FDA found

  1. The website offered unapproved new drugs, including tramadol, clonazepam, and amphetamine products, without FDA-approved applications.

    FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  2. The prescription drugs' labeling did not include adequate directions for use by a layperson, so FDA called them misbranded.

    FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  3. The website offered prescription drugs for sale without requiring a prescription, which FDA said misbrands the drugs while held for sale.

    FD&C Act sections 503(b)(1) and 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]
  4. By offering these drugs to U.S. consumers, the website caused misbranded drugs to be introduced into interstate commerce.

    FD&C Act section 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA asks citypharma.us to stop offering any unapproved and misbranded drugs for sale to U.S. consumers and to notify FDA in writing within 15 working days of the specific steps taken to address the violations and prevent recurrence, with supporting documents.

Who should pay attention

  • online pharmacies selling to U.S. consumers
  • telehealth or e-commerce platforms hosting drug sellers
  • brands and manufacturers whose drug names are used by unauthorized sellers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk